AC   CVCL_3422
SY   SUM-149PT; SUM 149PT; SUM149-PT; SUM149; SUM-149; SUM 149; 149 PT; 149PT; BrCL12
DR   BTO; BTO:0005475
DR   CLO; CLO_0009917
DR   EFO; EFO_0001240
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-11134
DR   ArrayExpress; E-TABM-157
DR   BioSample; SAMN03472959
DR   cancercelllines; CVCL_3422
DR   Cell_Model_Passport; SIDM01441
DR   ChEMBL-Cells; CHEMBL4295448
DR   ChEMBL-Targets; CHEMBL4296497
DR   CLS; 300609
DR   Cosmic; 1044208
DR   Cosmic; 1046959
DR   Cosmic; 1136379
DR   Cosmic; 1176631
DR   Cosmic; 1287929
DR   Cosmic; 1289411
DR   Cosmic; 1460239
DR   Cosmic; 1523966
DR   Cosmic; 1603224
DR   Cosmic; 2036674
DR   DepMap; ACH-001390
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM115105
DR   GEO; GSM217600
DR   GEO; GSM350549
DR   GEO; GSM421889
DR   GEO; GSM481335
DR   GEO; GSM501233
DR   GEO; GSM501234
DR   GEO; GSM501235
DR   GEO; GSM501237
DR   GEO; GSM501238
DR   GEO; GSM847433
DR   GEO; GSM847500
DR   GEO; GSM844705
DR   GEO; GSM1008916
DR   GEO; GSM1053736
DR   GEO; GSM1172992
DR   GEO; GSM1172897
DR   GEO; GSM1214568
DR   GEO; GSM1215280
DR   GEO; GSM1238140
DR   GEO; GSM1374911
DR   GEO; GSM1401669
DR   GEO; GSM3145734
DR   IARC_TP53; 24356
DR   LINCS_HMS; 51082
DR   PharmacoDB; SUM149PT_1509_2019
DR   PRIDE; PXD005295
DR   Progenetix; CVCL_3422
DR   PubChem_Cell_line; CVCL_3422
DR   SLKBase; 249
DR   Wikidata; Q54970832
RX   DOI=10.4172/2161-0681.1000119;
RX   PubMed=10424408;
RX   PubMed=10604729;
RX   PubMed=10700188;
RX   PubMed=10969801;
RX   PubMed=12353263;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=15857504;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=22032724;
RX   PubMed=23151021;
RX   PubMed=23401782;
RX   PubMed=23601657;
RX   PubMed=23784380;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26495931;
RX   PubMed=26589293;
RX   PubMed=26735014;
RX   PubMed=28287265;
RX   PubMed=32416067;
RX   PubMed=32715085;
RX   PubMed=35042871;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Characteristics: Derived from a mouse xenograft of a transplanted primary human invasive infiltrating ductal carcinoma metastatic nodule.
CC   Doubling time: 33.95 hours (GrayJW panel).
CC   HLA typing: A*68:01,68:01; B*53:01,78:01; C*06:02,16:01 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (PubMed=16397213; PubMed=19593635; PubMed=22032724).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (PubMed=10700188).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=16541312).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): CLS; DepMap; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D12S391: 15,18
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 14,15
ST   D19S433: 12,14
ST   D21S11: 28,31.2
ST   D2S1338: 20
ST   D3S1358: 17
ST   D5S818: 11
ST   D6S1043: 18
ST   D7S820: 11
ST   D8S1179: 14,16
ST   FGA: 29
ST   Penta D: 8,9
ST   Penta E: 11
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 16,18
DI   NCIt; C4001; Breast inflammatory carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   40Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
RX   DOI=10.4172/2161-0681.1000119;
RA   Robertson F.M., Chu K., Fernandez S.V., Mu Z.-M., Zhang X.-J., Liu H.,
RA   Boley K.M., Alpaugh R.K., Ye Z.-M., Wright M.C., Luo A.Z., Oraes R.,
RA   Wu H., Zook M., Barsky S.H., Krishnamurthy S., Cristofanilli M.;
RT   "Genomic profiling of pre-clinical models of inflammatory breast cancer
RT   identifies a signature of epithelial plasticity and suppression of
RT   TGFbeta signaling.";
RL   J. Clin. Exp. Pathol. 2:119.1-119.11(2012).
RX   PubMed=10424408; DOI=10.1023/A:1006135331912;
RA   Ignatoski K.M.W., Ethier S.P.;
RT   "Constitutive activation of pp125fak in newly isolated human breast
RT   cancer cell lines.";
RL   Breast Cancer Res. Treat. 54:173-182(1999).
RX   PubMed=10604729; DOI=10.1038/sj.bjc.6695007;
RA   Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A.,
RA   Kallioniemi O.-P., Ethier S.P.;
RT   "Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
RL   Br. J. Cancer 81:1328-1334(1999).
RX   PubMed=10700188; DOI=10.1038/73536;
RA   Gayther S.A., Batley S.J., Linger L., Bannister A.J., Thorpe K.,
RA   Chin S.-F., Daigo Y., Russell P., Wilson A., Sowter H.M.,
RA   Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.;
RT   "Mutations truncating the EP300 acetylase in human cancers.";
RL   Nat. Genet. 24:300-303(2000).
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
RX   PubMed=12353263; DOI=10.1002/gcc.10107;
RA   Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J.,
RA   Mozziconacci M.-J., Conte N., Murati A., Ginestier C.,
RA   Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C.,
RA   Birnbaum D., Chaffanet M.;
RT   "Reciprocal translocations in breast tumor cell lines: cloning of a
RT   t(3;20) that targets the FHIT gene.";
RL   Genes Chromosomes Cancer 35:204-218(2002).
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
RX   PubMed=15857504; DOI=10.1186/1475-2867-5-11;
RA   Hoffmeyer M.R., Wall K.M., Dharmawardhane S.F.;
RT   "In vitro analysis of the invasive phenotype of SUM 149, an
RT   inflammatory breast cancer cell line.";
RL   Cancer Cell Int. 5:11.1-11.10(2005).
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
RX   PubMed=22032724; DOI=10.1186/1755-8794-4-75;
RA   Ha K.C.H., Lalonde E., Li L.-L., Cavallone L., Natrajan R.,
RA   Lambros M.B., Mitsopoulos C., Hakas J., Kozarewa I., Fenwick K.,
RA   Lord C.J., Ashworth A., Vincent-Salomon A., Basik M., Reis-Filho J.S.,
RA   Majewski J., Foulkes W.D.;
RT   "Identification of gene fusion transcripts by transcriptome sequencing
RT   in BRCA1-mutated breast cancers and cell lines.";
RL   BMC Med. Genomics 4:75.1-75.13(2011).
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619.1-619.14(2012).
RX   PubMed=23401782; DOI=10.1155/2013/872743;
RA   Barnabas N., Cohen D.;
RT   "Phenotypic and molecular characterization of MCF10DCIS and SUM breast
RT   cancer cell lines.";
RL   Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
RX   PubMed=23784380; DOI=10.1007/s10549-013-2600-4;
RA   Fernandez S.V., Robertson F.M., Pei J.-M., Aburto-Chumpitaz L., Mu Z.-M.,
RA   Chu K., Alpaugh R.K., Huang Y., Cao Y., Ye Z.-M., Cai K.Q., Boley K.M.,
RA   Klein-Szanto A.J.P., Devarajan K., Addya S., Cristofanilli M.;
RT   "Inflammatory breast cancer (IBC): clues for targeted therapies.";
RL   Breast Cancer Res. Treat. 140:23-33(2013).
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26495931; DOI=10.1515/hmbci-2015-0024;
RA   Illera J.C., Caceres S., Pena L., de Andres P.J., Monsalve B.,
RA   Illera M.J., Woodward W.A., Reuben J.M., Silvan G.;
RT   "Steroid hormone secretion in inflammatory breast cancer cell lines.";
RL   Horm. Mol. Biol. Clin. Investig. 24:137-145(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26735014; DOI=10.1038/nature16508;
RA   Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P.,
RA   Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E.,
RA   Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C.,
RA   Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K.,
RA   Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E.,
RA   Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S.,
RA   Meyer C.A., Bradner J.E., Polyak K.;
RT   "Response and resistance to BET bromodomain inhibitors in
RT   triple-negative breast cancer.";
RL   Nature 529:413-417(2016).
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
RX   PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027;
RA   Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B.,
RA   Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K.,
RA   Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S.,
RA   Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W.,
RA   McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.D., Michel B.,
RA   Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S.,
RA   Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F.,
RA   Polyak K.;
RT   "Synthetic lethal and resistance interactions with BET bromodomain
RT   inhibitors in triple-negative breast cancer.";
RL   Mol. Cell 78:1096-1113.e8(2020).
RX   PubMed=32715085; DOI=10.1038/s41523-020-0173-z;
RA   Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C.,
RA   Duchinski K., Couch D., Gray J.W., Kappler C.S.;
RT   "Development and implementation of the SUM breast cancer cell line
RT   functional genomics knowledge base.";
RL   NPJ Breast Cancer 6:30.1-30.14(2020).
RX   PubMed=35042871; DOI=10.1038/s41523-021-00379-6;
RA   Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V.,
RA   Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L.,
RA   Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.;
RT   "Comparative transcriptional analyses of preclinical models and
RT   patient samples reveal MYC and RELA driven expression patterns that
RT   define the molecular landscape of IBC.";
RL   NPJ Breast Cancer 8:12.1-12.12(2022).